FULC Stock Price History and Quote Analysis Insights for Investors
Fulcrum Therapeutics, Inc.
Stock Price Today
Fulcrum Therapeutics, Inc. (FULC) stock declined over -1.74%, trading at $3.96 on NASDAQ, down from the previous close of $4.03. The stock opened at $4.02, fluctuating between $3.96 and $4.17 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Company Information
| Employees | 76 |
| Beta | 2.23 |
| Sales or Revenue | $2.81M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) stock price is $3.96 in the last trading session. During the trading session, FULC stock reached the peak price of $4.17 while $3.96 was the lowest point it dropped to. The percentage change in FULC stock occurred in the recent session was -1.74% while the dollar amount for the price change in FULC stock was -$0.07.
The NASDAQ listed FULC is part of Biotechnology industry that operates in the broader Healthcare sector. Fulcrum Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Prof. Jeannie T. Lee M.D., Ph.D.
Founder
Mr. Alexander C. Sapir
Chief Executive Officer, Pres & Director
Dr. Jeffrey W. Jacobs Ph.D.
Chief Scientific Officer
Dr. Bradley E. Bernstein M.D., Ph.D.
Founder
Mr. Bryan E. Stuart
Pres, Chief Executive Officer & Director
Mr. Mel Hayes
Chief Operating Officer
Dr. Judith A. Dunn Ph.D.
Interim Chief Medical Officer
Mr. Gregory Tourangeau
Controller & Principal Accounting Officer
Ms. Esther P. Rajavelu
Chief Financial Officer & Treasurer
Dr. Rudolf Jaenisch M.D., Ph.D.
Founder
Dr. Michael R. Green
Founder
Mr. Alan A. Musso C.M.A., C.P.A., CPA
Chief Financial Officer
Dr. Danny Reinberg
Founder
Mr. Alan A. Musso C.M.A., CPA, CPA
Chief Financial Officer
Dr. Robert J. Gould Ph.D.
Pres, Interim Chief Executive Officer & Director
Mr. Curtis G. Oltmans J.D.
Senior Vice President, Chief Legal Officer & Corporation Sec.
FULC's closing price is 38.46% higher than its 52-week low of $2.86 where as its distance from 52-week high of $13.70 is -71.09%.
Number of FULC employees currently stands at 76.
Official Website of FULC is: https://www.fulcrumtx.com
FULC could be contacted at phone 617 651 8851 and can also be accessed through its website. FULC operates from 26 Landsdowne Street, Cambridge, MA 02139, United States.
FULC stock volume for the day was 477.89K shares. The average number of FULC shares traded daily for last 3 months was 1.06M.
The market value of FULC currently stands at $213.60M with its latest stock price at $3.96 and 53.94M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com